Form 4: TriSalus Life Sciences CEO Acquires Shares in Open Market Transactions
SEC Form 4 Filing
TriSalus Life Sciences CEO, Mary T. Szela, purchased a total of 10,040 shares of common stock in two separate transactions on January 29th and 30th, 2025.
Summary
- Mary T. Szela, CEO and President of TriSalus Life Sciences, acquired 5,030 shares of common stock on January 29, 2025, at a price of $5.03 per share.
- She then purchased an additional 5,010 shares on January 30, 2025, at a weighted average price of $5.28 per share, with individual prices ranging from $5.15 to $5.33.
- Following these transactions, Ms. Szela directly owns a total of 444,259 shares of TriSalus Life Sciences common stock.
Sentiment
Score: 7
Explanation: The document reflects a positive sentiment due to the CEO's purchase of shares, indicating confidence in the company. However, it is a routine transaction and not a major event.
Positives
- The CEO's purchase of shares could be seen as a positive signal of confidence in the company's future prospects.
- The increased ownership aligns the CEO's interests more closely with those of other shareholders.
Industry Context
This type of transaction is common for company executives and is often seen as a sign of confidence in the company's future. It is a routine disclosure required by the SEC.
Comparison to Industry Standards
- Insider buying is a common practice across the industry, with executives often purchasing shares in their own companies.
- The size of the transaction is relatively small compared to some insider purchases, but it is still a notable event given the CEO's position.
- Similar transactions are regularly reported by executives at comparable companies, such as those in the biotechnology and pharmaceutical sectors.
Stakeholder Impact
- The CEO's share purchase may positively influence investor confidence.
- The transaction has no direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 01/29/2025 | CEO purchased 5,030 shares of common stock at $5.03 per share. |
| 01/30/2025 | CEO purchased 5,010 shares of common stock at a weighted average price of $5.28 per share. |
| 01/31/2025 | Date of filing of the SEC Form 4. |
Keywords
TriSalus Life Sciences, CEO, Mary T. Szela, stock purchase, insider trading, common stock, share acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.